/
Oncology
Recurrent Diffuse Large B-Cell Lymphoma
19
Pipeline Programs↗
7
Active Trials↗
11
Companies Involved↗
Recurrent Diffuse Large B-Cell Lymphoma is an emerging landscape with 19 programs across 11 companies. The most active players are Regeneron.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 15
Phase 212
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
61%
Small molecule
11 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.
Analysis
Trial Status
10
clinical trials
Recruiting6 · 60%
Completed2 · 20%
Suspended1 · 10%
Not yet recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Recruiting·—·Preclinical·NCT06536049·38 enrolled
A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma
Not yet recruiting·—·Phase 1·NCT07676877·18 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)